Tata India Pharma & HealthCare Fund
The scheme seeks long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Growthvine rating: 3/5 — ranked #33 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹30.19 (as of 2026-10-23) |
|---|
| AUM | ₹1,511 Cr |
|---|
| Expense ratio | 1.80% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Rajat Srivastava |
|---|
| Exit load | 0.25% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 12.34% |
|---|
| Sharpe ratio | 0.68 |
|---|
| Standard deviation | 16.71% |
|---|
| Max drawdown | −21.94% |
|---|
| Alpha | -3.01 |
|---|
| Beta | 0.99 |
|---|
Over 5 years, captured 93.6% of NIFTY Pharma's upside and 93.4% of its downside.
Market cap allocation
| Large cap | 26.1% |
|---|
| Mid cap | 34.0% |
|---|
| Small cap | 40.0% |
|---|
Concentration
| Top 5 holdings | 30.2% |
|---|
| Top 10 holdings | 50.5% |
|---|
| Total holdings | 41 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.0%
- Abbott India Ltd. — 5.9%
- HealthCare Global Enterprises Limited — 5.9%
- Divis Laboratories Ltd. — 5.7%
- Dr. Reddys Laboratories Ltd. — 4.7%
- Apollo Hospitals Enterprises Ltd. — 4.4%
- Rainbow Childrens Medicare Limited — 4.3%
- Cipla Ltd. — 4.2%
- Torrent Pharmaceuticals Ltd. — 3.8%
- Max Healthcare Institute Limited — 3.7%
Top sectors
- Pharma & Biotech — 60.6%
- Healthcare — 28.3%
- Fertilisers — 6.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −0.1% | Q2 | #25 of 76 |
| 2025 | −4.9% | Q4 (Bottom) | #56 of 69 |
| 2024 | 40.4% | Q1 (Top) | #9 of 58 |
| 2023 | 36.6% | Q3 | #25 of 48 |
| 2022 | −8.0% | Q3 | #35 of 46 |